Cannabis patients comprise 1% of over 100 million US residents with qualifying conditions such as chronic pain, PTSD, cancer induced nausea and vomiting (CINV), cachexia, neurodegenerative disorders, seizure disorders, spasticity disorders, diabetes, HIV/AIDS, and glaucoma. This “therapeutic gap” exists in large part due to the lack of credible, clinically useful information about cannabis for patients and health care professionals. A 1% prescription rate for medical marijuana corresponds to the prescription rate observed in surveys of physicians practicing in specialties where cannabis is part of the treatment armamentaria. The fact that between 5-7% of surveyed physicians prescribed a synthetic cannabis analog quantifies the potential for broadening usage of medical cannabis.

420 InSight sees a historic opportunity to use health information to improve care for one million patients already using cannabis, and to increase access to medical cannabis as appropriate for all patients with qualifying conditions. Cannabis patients who have received their...